EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieMultizentrische Studie

Neoadjuvant Chemotherapy With Oxaliplatin and Fluoropyrimidine Versus Upfront Surgery for Locally Advanced Colon Cancer: The Randomized, Phase III OPTICAL Trial

Neoadjuvante Chemotherapie mit Oxaliplatin und Fluoropyrimidin versus primäre Operation bei lokal fortgeschrittenem Kolonkarzinom: die randomisierte Phase-III-OPTICAL-Studie

Huabin Hu iD, Jianwei Zhang iD, Yunfeng Li, Xiaozhong Wang, Ziqiang Wang iD, Hui Wang iD, Liang Kang iD, Ping Liu, Ping Lan iD, Xiaojian Wu iD, Yunhuan Zhen iD, Haiping Pei und 39 weitere

Journal of Clinical Oncology · 2024-09 · 42 (25) · 2978-2988

DOI: 10.1200/jco.23.01889 ↗

Auf einen Blick

In der OPTICAL-Studie führte eine neoadjuvante Chemotherapie nicht zu einem signifikanten Vorteil im 3-Jahres-DFS. Es zeigte sich jedoch eine pathologische Tumor-Downstaging und ein möglicher OS-Vorteil.

Fragestellung

Verbessert eine 3-monatige neoadjuvante Chemotherapie mit mFOLFOX6 oder CAPOX gegenüber sofortiger Operation die Outcomes bei lokal fortgeschrittenem Kolonkarzinom?

Methode

Randomisierte Phase-III-Studie bei klinisch lokal fortgeschrittenem Kolonkarzinom; 1:1-Zuteilung zu 6 präoperativen Zyklen mFOLFOX6 oder 4 Zyklen CAPOX mit anschließender Operation und adjuvanter Chemotherapie versus sofortige Operation und adjuvante Chemotherapie nach Wahl der Ärzt:innen.

Ergebnisse

744 Patient:innen in der mITT-Analyse (371 NAC; 373 upfront surgery). 3-Jahres-DFS: 82,1 % vs. 77,5 %; HR 0,74 (95 %-KI 0,54–1,03). R0-Resektion in beiden Gruppen bei 98 %. pCR 7 %, pT3-4 77 % vs. 94 %, pN1-2 31 % vs. 46 %, OS-HR 0,44 (95 %-KI 0,25–0,77).

Schlussfolgerung der Autor:innen

Die neoadjuvante Therapie mit mFOLFOX6 oder CAPOX zeigte keinen signifikanten DFS-Vorteil. Sie war sicher und führte zu einer deutlichen pathologischen Downstaging; sie erscheint als praktikable Option.

Kernaussagen

  • Kein signifikanter Vorteil im 3-Jahres-DFS
  • 3-Jahres-DFS: 82,1 % vs. 77,5 %; HR 0,74
  • Pathologisches Downstaging und möglicher OS-Vorteil

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Journal of Clinical Oncology, 2024-09. Verfasst von Huabin Hu und 50 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, People's Republic of China. Hauptthemen laut MEDLINE: Colonic Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Neoadjuvant Therapy, Oxaliplatin. Die Arbeit wurde bisher 90-mal zitiert (Crossref) und nennt 45 Literaturangaben.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE The role of neoadjuvant chemotherapy (NAC) in colon cancer remains unclear. This trial investigated whether 3 months of modified infusional fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or capecitabine and oxaliplatin (CAPOX) as NAC could improve outcomes in patients with locally advanced colon cancer versus upfront surgery. PATIENTS AND METHODS OPTICAL was a randomized, phase III trial in patients with clinically staged locally advanced colon cancer (T3 with extramural spread into the mesocolic fat ≥5 mm or T4). Patients were randomly assigned 1:1 to receive six preoperative cycles of mFOLFOX6 or four cycles of CAPOX, followed by surgery and adjuvant chemotherapy (NAC group), or immediate surgery and the physician's choice of adjuvant chemotherapy (upfront surgery group). The primary end point was 3-year disease-free survival (DFS) assessed in the modified intention-to-treat (mITT) population. RESULTS Between January 2016 and April 2021, of the 752 patients enrolled, 744 patients were included in the mITT analysis (371 in the NAC group; 373 in the upfront surgery group). At a median follow-up of 48.0 months (IQR, 46.0-50.1), 3-year DFS rates were 82.1% in the NAC group and 77.5% in the upfront surgery group (stratified hazard ratio [HR], 0.74 [95% CI, 0.54 to 1.03]). The R0 resection was achieved in 98% of patients who underwent surgery in both groups. Compared with upfront surgery, NAC resulted in a 7% pathologic complete response rate (pCR), significantly lower rates of advanced tumor staging (pT3-4: 77% v 94%), lymph node metastasis (pN1-2: 31% v 46%), and potentially improved overall survival (stratified HR, 0.44 [95% CI, 0.25 to 0.77]). CONCLUSION NAC with mFOLFOX6 or CAPOX did not show a significant DFS benefit. However, this neoadjuvant approach was safe, resulted in substantial pathologic downstaging, and appears to be a viable therapeutic option for locally advanced colon cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colonic NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsNeoadjuvant TherapyOxaliplatinFluorouracilLeucovorinHumansMaleFemaleMiddle AgedAgedCapecitabineChemotherapy, AdjuvantDisease-Free SurvivalAdultNeoplasm StagingColectomyOrganoplatinum Compounds

Substanzen

OxaliplatinFluorouracilLeucovorinCapecitabineOrganoplatinum Compounds

Autor:innen und Institutionen

  • Department of Medical Oncology, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, People's Republic of China.
  • Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, Guangzhou, People's Republic of China.
  • Biomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, People's Republic of China.
  • Department of Colorectal Surgery, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Kunming, People's Republic of China.
  • Department of Gastrointestinal Surgery, Shantou Central Hospital, Shantou, People's Republic of China.
  • Department of General Surgery, Colorectal Cancer Center, West China Hospital, Sichuan University, Chengdu, People's Republic of China.

ORCID-Profile: Huabin Hu, Jianwei Zhang, Ziqiang Wang, Hui Wang, Liang Kang, Ping Lan, Xiaojian Wu, Yunhuan Zhen, Hongbo Wei, Kefeng Ding, Wei Zhang, Zonghai Huang, Yandong Zhao, Xiaoyu Xie, Lishuo Shi, Yanhong Deng

Zitieren

APA

Hu, H., Zhang, J., Li, Y., Wang, X., Wang, Z., Wang, H., Kang, L., Liu, P., Lan, P., Wu, X., Zhen, Y., Pei, H., Huang, Z., Zhang, H., Chen, W., Zeng, Y., Lai, J., Wei, H., Huang, X., …, & OPTICAL study group (2024). Neoadjuvant Chemotherapy With Oxaliplatin and Fluoropyrimidine Versus Upfront Surgery for Locally Advanced Colon Cancer: The Randomized, Phase III OPTICAL Trial. Journal of Clinical Oncology, 42(25), 2978-2988. https://doi.org/10.1200/jco.23.01889

Vancouver

Hu H, Zhang J, Li Y, Wang X, Wang Z, Wang H, et al. Neoadjuvant Chemotherapy With Oxaliplatin and Fluoropyrimidine Versus Upfront Surgery for Locally Advanced Colon Cancer: The Randomized, Phase III OPTICAL Trial. Journal of Clinical Oncology. 2024;42(25):2978-2988. doi:10.1200/jco.23.01889

BibTeX
@article{Hu2024,
  author = {Hu, Huabin and Zhang, Jianwei and Li, Yunfeng and Wang, Xiaozhong and Wang, Ziqiang and Wang, Hui and Kang, Liang and Liu, Ping and Lan, Ping and Wu, Xiaojian and Zhen, Yunhuan and Pei, Haiping and Huang, Zhongcheng and Zhang, Hao and Chen, Wenbin and Zeng, Yongming and Lai, Jiajun and Wei, Hongbo and Huang, Xuefeng and Chen, Jiansi and Chen, Jigui and Tao, Kaixiong and Xu, Qingwen and Peng, Xiang and Liang, Junlin and Cai, Guanfu and Ding, Kefeng and Ding, Zhijie and Hu, Ming and Zhang, Wei and Tang, Bo and Hong, Chuyuan and Cao, Jie and Huang, Zonghai and Cao, Wuteng and Li, Fangqian and Wang, Xinhua and Wang, Chao and Huang, Yan and Zhao, Yandong and Cai, Yue and Ling, Jiayu and Xie, Xiaoyu and Wu, Zehua and Shi, Lishuo and Ling, Li and Liu, Hao and Wang, Jianping and Huang, Meijin and Deng, Yanhong and OPTICAL study group, OPTICAL study group},
  title = {Neoadjuvant Chemotherapy With Oxaliplatin and Fluoropyrimidine Versus Upfront Surgery for Locally Advanced Colon Cancer: The Randomized, Phase III OPTICAL Trial},
  journal = {Journal of Clinical Oncology},
  year = {2024},
  volume = {42},
  number = {25},
  pages = {2978--2988},
  doi = {10.1200/jco.23.01889}
}
Kostenlos starten →